RhumbLine Advisers
CRMD icon

RhumbLine Advisers’s CorMedix CRMD Stock Holding History

RhumbLine Advisers’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$582K Sell
85,711
-366
-0.4% -$2.71K ﹤0.01% 2514
2025
Q4 		$1M Sell
86,077
-9,475
-10% -$105K ﹤0.01% 2221
2025
Q3 		$1.11M Buy
95,552
+2,647
+3% +$32K ﹤0.01% 2189
2025
Q2 		$1.14M Buy
92,905
+11,340
+14% +$125K ﹤0.01% 2178
2025
Q1 		$502K Buy
81,565
+5,818
+8% +$60.2K ﹤0.01% 2574
2024
Q4 		$614K Buy
75,747
+6,028
+9% +$60.2K ﹤0.01% 2534
2024
Q3 		$563K Sell
69,719
-4,520
-6% -$24.5K ﹤0.01% 2624
2024
Q2 		$321K Buy
74,239
+11,339
+18% +$57.6K ﹤0.01% 2956
2024
Q1 		$267K Sell
62,900
-5,982
-9% -$20.7K ﹤0.01% 3041
2023
Q4 		$259K Buy
68,882
+12,186
+21% +$41.9K ﹤0.01% 3048
2023
Q3 		$210K Buy
56,696
+7,141
+14% +$28.4K ﹤0.01% 3137
2023
Q2 		$196K Buy
+49,555
New +$245K ﹤0.01% 3248
2022
Q2 		– Sell
-42,331
Closed -$232K – 3123
2022
Q1 		$232K Sell
42,331
-1,018
-2% -$4.66K ﹤0.01% 2723
2021
Q4 		$197K Sell
43,349
-7
-0% -$35 ﹤0.01% 2838
2021
Q3 		$202K Buy
43,356
+317
+0.7% +$1.85K ﹤0.01% 2912
2021
Q2 		$295K Buy
43,039
+18,488
+75% +$147K ﹤0.01% 2791
2021
Q1 		$245K Sell
24,551
-1,870
-7% -$19.7K ﹤0.01% 2772
2020
Q4 		$196K Buy
26,421
+6,081
+30% +$41.3K ﹤0.01% 2844
2020
Q3 		$123K Sell
20,340
-4,115
-17% -$20.7K ﹤0.01% 2829
2020
Q2 		$154K Buy
24,455
+4,993
+26% +$23.1K ﹤0.01% 2855
2020
Q1 		$70K Hold
19,462
– – ﹤0.01% 2833
2019
Q4 		$142K Buy
19,462
+132
+0.7% +$807 ﹤0.01% 2828
2019
Q3 		$123K Buy
19,330
+730
+4% +$6.13K ﹤0.01% 2851
2019
Q2 		$167K Buy
+18,600
New +$146K ﹤0.01% 2834
2016
Q2 		– Sell
-6,987
Closed -$93K – 2990
2016
Q1 		$93K Buy
6,987
+1,010
+17% +$9.8K ﹤0.01% 2906
2015
Q4 		$61K Buy
5,977
+618
+12% +$7.12K ﹤0.01% 2991
2015
Q3 		$53K Buy
5,359
+225
+4% +$3.47K ﹤0.01% 2990
2015
Q2 		$100K Buy
+5,134
New +$176K ﹤0.01% 3005

Other funds holding CRMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

RhumbLine Advisers's CRMD Position: Q1 2026 in Review

RhumbLine Advisers reduced its CorMedix (CRMD) stake by 0.43% in Q1 2026, selling an estimated $2.71K and leaving 85,711 shares worth $582K. The position accounts for ﹤0.01% of the portfolio, ranked #2514.

RhumbLine Advisers first reported a position in CRMD in Q2 2015 and has held it in 28 quarters since. The position peaked at $1.14M in Q2 2025. 187 funds tracked by Wall St. Rank hold CRMD as of Q1 2026.

  • RhumbLine Advisers held 85,711 shares of CorMedix worth $582K as of Q1 2026.
  • RhumbLine Advisers sold 366 CorMedix shares in Q1 2026, an estimated $2.71K.
  • CorMedix made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2514 holding.
  • RhumbLine Advisers first reported a position in CorMedix in Q2 2015 and has held it in 28 quarters since.
  • RhumbLine Advisers's CorMedix position peaked at $1.14M in Q2 2025.
  • 187 funds tracked by Wall St. Rank held CorMedix as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.